Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2025-04-19
Target enrollment:
Participant gender:
Summary
This is a phase I, single arm, non-randomized, open label, treatment study trial to determine
the recommended phase II dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with
refractory systemic lupus erythematosus.